Antimicrobial susceptibility trends for urinary isolates in the veteran population

Schappert, 2011, Ambulatory medical care utilization estimates for 2007, Vital Health Stat, 13, 1 Foxman, 2014, Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden, Infect Dis Clin North Am, 28, 1, 10.1016/j.idc.2013.09.003 Schaeffer, 2016, Urinary tract infections in older men, N Engl J Med, 374, 2192, 10.1056/NEJMcp1503950 Gupta, 2011, International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious diseases, Clin Infect Dis, 52, e103, 10.1093/cid/ciq257 Lob, 2016, Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014, Diagn Microbiol Infect Dis, 85, 459, 10.1016/j.diagmicrobio.2016.04.022 Sanchez, 2016, Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012, Antimicrob Agents Chemother, 60, 2680, 10.1128/AAC.02897-15 2020 Rank, 2018, Antimicrobial susceptibility trends observed in urinary pathogens obtained from new york state, Open Forum Infect Dis, 5, ofy297, 10.1093/ofid/ofy297 Schito, 2009, The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections, Int J Antimicrob Agents, 34, 407, 10.1016/j.ijantimicag.2009.04.012 US Department of Health HSFaDA. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Published 2018. Available at:https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side. Accessed April 17, 2020. US Department of Health HSFaDA. FDA drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. US Department of Health, Human Services Food and Drug Administration. Published 2016. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain. Accessed April 17, 2020. Chiu, 2017, Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms, J Microbiol Immunol Infect, 50, 879, 10.1016/j.jmii.2016.08.008 Wargo, 2014, Aminoglycoside-induced nephrotoxicity, J Pharm Pract, 27, 573, 10.1177/0897190014546836 Streetman, 2001, Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs, Pharmacotherapy, 21, 443, 10.1592/phco.21.5.443.34490